SCRI Development Innovations, LLC

Ownership
Private
Employees
-
Market Cap
-
Website

Trial of Poor Performance Status Patients (ToPPS)

First Posted Date
2009-05-04
Last Posted Date
2015-05-15
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
172
Registration Number
NCT00892710
Locations
🇺🇸

Aventura Medical Center, Aventura, Florida, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Memorial Regional Cancer Center, Hollywood, Florida, United States

and more 24 locations

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

First Posted Date
2009-04-24
Last Posted Date
2016-09-07
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
54
Registration Number
NCT00887575
Locations
🇺🇸

Holy Cross Hospital, Ft. Lauderdale, Florida, United States

🇺🇸

Florida Cancer Specialists North, Ft. Myers, Florida, United States

🇺🇸

National Capital Clinical Research Consortium, Bethesda, Maryland, United States

and more 11 locations

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

First Posted Date
2009-04-07
Last Posted Date
2010-08-04
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
200
Registration Number
NCT00877045
Locations
🇺🇸

Georgia Cancer Specialists, Atlanta, Georgia, United States

🇺🇸

Virginia Cancer Institute, Richmond, Virginia, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

and more 2 locations

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Completed
Conditions
First Posted Date
2009-04-06
Last Posted Date
2013-11-14
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
47
Registration Number
NCT00876382
Locations
🇺🇸

Medical Oncology Associates of Augusta, Augusta, Georgia, United States

🇺🇸

St. Louis Cancer Care, Chesterfield, Missouri, United States

🇺🇸

Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States

and more 5 locations

Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

Completed
Conditions
First Posted Date
2009-04-06
Last Posted Date
2013-12-04
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
30
Registration Number
NCT00876408
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Completed
Conditions
First Posted Date
2009-04-06
Last Posted Date
2011-11-21
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
198
Registration Number
NCT00876070
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Georgia Cancer Specialists, Atlanta, Georgia, United States

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-03-23
Last Posted Date
2021-11-22
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
168
Registration Number
NCT00866905
Locations
🇺🇸

St. Louis Cancer Care, Chesterfield, Missouri, United States

🇺🇸

South Carolina Oncology Associates, PA, Columbia, South Carolina, United States

🇺🇸

Aventura Medical Center, Aventura, Florida, United States

and more 17 locations

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

First Posted Date
2009-02-05
Last Posted Date
2013-03-13
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
72
Registration Number
NCT00837031
Locations
🇺🇸

Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Oncology Hematology Care, Cincinnati, Ohio, United States

and more 6 locations

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-01-21
Last Posted Date
2014-12-22
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
83
Registration Number
NCT00825734
Locations
🇺🇸

Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States

🇺🇸

Florida Cancer Specialists, Ft. Myers, Florida, United States

🇺🇸

St. Louis Cancer Care, Chesterfield, Missouri, United States

and more 12 locations

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

First Posted Date
2009-01-14
Last Posted Date
2014-12-22
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
60
Registration Number
NCT00821886
Locations
🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Medical Oncology Associates of Augusta, Augusta, Georgia, United States

🇺🇸

Mercy Hospital, Portland, Maine, United States

and more 9 locations
© Copyright 2024. All Rights Reserved by MedPath